Life sciences firm LGC announced Monday that it is acquiring Technopath Clinical Diagnostics, a manufacturer of quality control solutions for clinical laboratories, for an undisclosed amount.
Technopath’s chemistry and immunoassay controls will be brought into LGC’s clinical diagnostics business unit.
Other terms of the agreement were not disclosed.
LGC President and COO Euan O’Sullivan said in a statement that Technopath’s “multi-constituent quality control products will dovetail perfectly with the calibration verification, molecular and serology product portfolios within our Clinical Diagnostics business unit.”
The CEO of Tipperary, Ireland-based Technopath, Malcolm Bell, added that the firm’s “multi analyte QC products allow end-customer labs to optimise their entire QC testing strategy while reducing waste and storage requirements and, most importantly, reporting patient results with enhanced confidence and greater accuracy.”
Last year, London-based LGC acquired the infectious disease antigen and antibody supplier Native Antigen Company.